Dengue vaccine: hypotheses to understand CYD-TDV-induced protection - PubMed (original) (raw)

Review

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

Bruno Guy et al. Nat Rev Microbiol. 2016 Jan.

Abstract

Dengue virus (DENV) is a human pathogen with a large impact on public health. Although no vaccine against DENV is currently licensed, a recombinant vaccine - chimeric yellow fever virus-DENV tetravalent dengue vaccine (CYD-TDV) - has shown efficacy against symptomatic dengue disease in two recent Phase III clinical trials. Safety observations were also recently reported for these trials. In this Opinion article, we review the data from recent vaccine clinical trials and discuss the putative mechanisms behind the observed efficacy of the vaccine against different forms of the disease, focusing on the interactions between the infecting virus, pre-existing host immunity and vaccine-induced immune responses.

PubMed Disclaimer

References

1. 1. Am J Trop Med Hyg. 2015 Apr;92(4):698-708 - PubMed
2. 1. J Infect Dis. 2013 Sep;208(6):1026-33 - PubMed
3. 1. J Immunol. 2012 Jan 1;188(1):404-16 - PubMed
4. 1. Am J Dis Child. 1991 Nov;145(11):1285-9 - PubMed
5. 1. J Infect Dis. 2015 Feb 15;211(4):590-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information